# PHARMACYTE BIOTECH, INC. (PMCB) · Edgar & Edgarette company card

> Pharmacyte Biotech (PMCB) reported revenue of $0 million in FY2026, operating margin null against a -15.8% median for biological products, (no diagnostic substances), equity 71.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1157075 · fiscal year ended 2026-04-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/PMCB) · [JSON](https://www.pops4.com/boards/company/PMCB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$5M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $19M |
| Long-term debt | — |
| Total assets | $47M |
| Total equity | $33M |
| Equity ÷ assets | 71.2% |
| Return on equity | -58.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.16 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · filed late quarterly report notice, auditor change in the last 12 months; operating cash flow was negative (-$5.2M in FY2026); operating loss: a margin of -Infinity% in FY2026

## Edgarette's reading

Exposure: revenue $0K (FY2026). Experience: one year on record; operating margin null, up from null. Soundness: equity 71.2% of assets, return on equity -58.3%. Credibility: four or more audited years, reasonable weight. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin null against a -15.8% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2025-12-05 ([filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316825008947/0001683168-25-008947-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2025-12-15 ([filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316825009154/0001683168-25-009154-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-10-16 ([filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007934/0001683168-26-007934-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-04-02 ([filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/0001683168-26-002613-index.htm))

## Recent filings

- 8-K · filed 2026-11-19 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826008964/0001683168-26-008964-index.htm)
- 8-K · filed 2026-11-13 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826008705/0001683168-26-008705-index.htm)
- 8-K · filed 2026-10-16 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007934/0001683168-26-007934-index.htm)
- 10-Q · filed 2026-09-14 · [filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007106/0001683168-26-007106-index.htm)
- 10-K · filed 2026-07-29 · [filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/0001683168-26-005836-index.htm)
- 8-K · filed 2026-04-02 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/0001683168-26-002613-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001157075.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1157075

## Cite

POPS4, Edgar & Edgarette: PHARMACYTE BIOTECH, INC. (PMCB) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/PMCB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

